Poster Abstract from ID Week 2016 – Reducing SSIR Rates with Nozin Nasal Sanitizer

January 27, 2017

Baylor Orthopedic and Spine Hospital at Arlington, Texas presented a poster at ID Week 2016: Pre- and Post-Operative Participation of Orthopedic Patients and Surgical Staff in a Novel Intervention to Reduce Staphylococcus aureus Infection.

The premise of the poster abstract presentation was "overall reduction of potentially infectious bacteria in the immediate patient environment is critical to effective infection control (IC) during both pre- and post-surgical periods. This study was designed to determine if Staphylococcus aureus surgical site infection rates (SSIR) could be reduced by the inclusion of patients and their most proximal healthcare personnel in nasal carriage reduction using an alcohol-based nasal antiseptic along with pre-existing IC protocols."

For this Baylor study: “The inclusion of alcohol-based nasal antiseptic use by both surgical patients and staff in IC protocols during the peri-operative period resulted in a marked decrease in SSIR.”  The antiseptic was Nozin® Nasal Sanitizer®. The study summary stated: “The addition of nasal antiseptic to our standard procedures for reducing skin carriage resulted in a marked and significant decrease in S. aureus SSIs.”

Nozin Nasal Sanitizer is an effective method for nasal decolonization and may be used in tandem with infection control protocols already in place, like pre-operative chlorhexidine gluconate bathing. The following methodology was used by Baylor in the study: "During the three prior quarters that served as the study baseline, surgical IC protocols included pre-operative chlorhexidine gluconate bathing that was sometimes combined with patient-applied nasal mupirocin ointment prior to admission. During the three consecutive quarters of the study period in our spine surgery group, the IC protocol was amended to include nasal patient decolonization using an alcohol-based antiseptic by nursing staff during pre-operative preparation, while in the post-anesthesia care unit (PACU) and on a daily basis until discharge. To foster carriage reduction post-discharge, patients were instructed to continue applications for 5-7 days using the remaining antiseptic. In addition, surgeons and surgical staff agreed to self-decolonize prior to each surgery, as did corresponding PACU staff. Nasal antiseptic use by floor nursing personnel was strongly encouraged and facilitated."

Nozin ID Week

Learn more about Nozin Nasal Sanitizer's Pre-Op Pack

Benefits of Nozin® Nasal Sanitizer® use in your facility

An important, new paradigm, Nozin® Nasal Sanitizer® offers an innovative tool for fast and easy nasal carriage reduction without antibiotics that is clinically proven to reduce Staph aureus carriage.* This infection control breakthrough can be used to:

  • Decreased bacterial burden contributes to reduced risk of infection in patients and staff
  • Improve Staph aureus prevention
  • Provide sense of more secure, healthier environment for patients 
  • Increase attention to wellness of staff for workplace health and employee satisfaction

Nozin® Nasal Sanitizer® antiseptic can provide a new tool to help in the control of nasal colonization by potentially pathogenic bacteria, such as Staph aureus, without antibiotics.

  • Nasal Sanitizer® targets a critical point of carriage
  • Kills 99.99% of germs
  • Broad spectrum efficacy
  • Proven safe and effective
  • Clinically shown to reduce nasal carriage, without antibiotics
  • Reducing nasal carriage without antibiotics conforms with antibiotic steqrdship

Nozin® Nasal Sanitizer® is currently being implemented and used daily by staff and patients in facilities and hospitals across the country.

Health Professionals:
Request a comprehensive analysis of your colonization risk mitigation protocols today.

© 2004-2023 Global Life Technologies Corp. All rights reserved. All trademarks are property of their respective owners. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.